Application 210632
- Type
- NDA
- Sponsor
- FRESENIUS KABI USA
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | SOLUTION;INTRAVENOUS | 100MCG/5ML (20MCG/ML) | Yes | Yes |
| 002 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | SOLUTION;INTRAVENOUS | 200MCG/5ML (40MCG/ML) | Yes | Yes |
| 003 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | SOLUTION;INTRAVENOUS | 500MCG/5ML (100MCG/ML) | Yes | Yes |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N210632-001 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | |
| N210632-002 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | |
| N210632-003 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 |
Orange Book patents#
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N210632-001 | 10398669 | 2036-12-01 | Drug product | 2019-09-13 | |
| N210632-001 | 11135190 | 2036-12-01 | Drug product | 2021-10-07 | |
| N210632-001 | 12636270 | 2036-12-01 | Drug product | 2026-06-18 | |
| N210632-001 | 9782376 | 2036-12-01 | Drug product | 2019-06-11 | |
| N210632-002 | 10398669 | 2036-12-01 | Drug product | 2019-09-13 | |
| N210632-002 | 11135190 | 2036-12-01 | Drug product | 2021-10-07 | |
| N210632-002 | 12636270 | 2036-12-01 | Drug product | 2026-06-18 | |
| N210632-002 | 9782376 | 2036-12-01 | Drug product | 2019-06-11 | |
| N210632-003 | 10398669 | 2036-12-01 | Drug product | 2019-09-13 | |
| N210632-003 | 11135190 | 2036-12-01 | Drug product | 2021-10-07 | |
| N210632-003 | 12636270 | 2036-12-01 | Drug product | 2026-06-18 | |
| N210632-003 | 9782376 | 2036-12-01 | Drug product | 2019-06-11 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N210632-002 | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 79d66fd596c7… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N210632-003 | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N210632-001 | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 301d65b070ca… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N210632-002 | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 301d65b070ca… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N210632-003 | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N210632-001 | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 1e350fbaab3a… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N210632-002 | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 1e350fbaab3a… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N210632-003 | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N210632-001 | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 8072bd15b7f6… | |
| 2024-05-31 18:47 UTC | 2024-05 | N210632-002 | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 8072bd15b7f6… | |
| 2024-05-31 18:47 UTC | 2024-05 | N210632-003 | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N210632-001 | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N210632-002 | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N210632-003 | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | N210632-001 | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 5d02ea3f76ae… | |
| 2022-04-08 23:34 UTC | 2022-04 | N210632-002 | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 5d02ea3f76ae… | |
| 2022-04-08 23:34 UTC | 2022-04 | N210632-003 | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | N210632-001 | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 4b0b4de00fa7… | |
| 2022-04-04 05:41 UTC | 2022-04 | N210632-002 | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 4b0b4de00fa7… | |
| 2022-04-04 05:41 UTC | 2022-04 | N210632-003 | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | N210632-001 | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N210632-002 | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N210632-003 | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | N210632-001 | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | bb7c543d1eb4… | |
| 2022-03-09 01:35 UTC | 2022-03 | N210632-002 | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | bb7c543d1eb4… | |
| 2022-03-09 01:35 UTC | 2022-03 | N210632-003 | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | N210632-001 | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 782e0a99824c… | |
| 2021-12-28 21:50 UTC | 2021-12 | N210632-002 | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 782e0a99824c… | |
| 2021-12-28 21:50 UTC | 2021-12 | N210632-003 | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N210632-001 | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 87673890dc5c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N210632-002 | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 87673890dc5c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N210632-003 | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | N210632-001 | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 5aa47cf7b7d7… | |
| 2021-03-12 10:30 UTC | 2021-03 | N210632-002 | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 5aa47cf7b7d7… | |
| 2021-03-12 10:30 UTC | 2021-03 | N210632-003 | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | N210632-001 | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 8869cabd3fbd… | |
| 2020-12-22 03:56 UTC | 2020-12 | N210632-002 | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 8869cabd3fbd… | |
| 2020-12-22 03:56 UTC | 2020-12 | N210632-003 | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | N210632-001 | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | c0c555d07b60… | |
| 2020-11-12 02:37 UTC | 2020-11 | N210632-002 | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | c0c555d07b60… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N210632-001 | 10398669 | 2036-12-01 | Drug product | 2019-09-13 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N210632-001 | 11135190 | 2036-12-01 | Drug product | 2021-10-07 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N210632-001 | 12636270 | 2036-12-01 | Drug product | 2026-06-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N210632-001 | 9782376 | 2036-12-01 | Drug product | 2019-06-11 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N210632-002 | 10398669 | 2036-12-01 | Drug product | 2019-09-13 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N210632-002 | 11135190 | 2036-12-01 | Drug product | 2021-10-07 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N210632-002 | 12636270 | 2036-12-01 | Drug product | 2026-06-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N210632-002 | 9782376 | 2036-12-01 | Drug product | 2019-06-11 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N210632-003 | 10398669 | 2036-12-01 | Drug product | 2019-09-13 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N210632-003 | 11135190 | 2036-12-01 | Drug product | 2021-10-07 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N210632-003 | 12636270 | 2036-12-01 | Drug product | 2026-06-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N210632-003 | 9782376 | 2036-12-01 | Drug product | 2019-06-11 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | N210632-001 | 10398669 | 2036-12-01 | Drug product | 2019-09-13 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N210632-001 | 11135190 | 2036-12-01 | Drug product | 2021-10-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N210632-001 | 12636270 | 2036-12-01 | Drug product | 2026-06-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N210632-001 | 9782376 | 2036-12-01 | Drug product | 2019-06-11 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N210632-002 | 10398669 | 2036-12-01 | Drug product | 2019-09-13 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N210632-002 | 11135190 | 2036-12-01 | Drug product | 2021-10-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N210632-002 | 12636270 | 2036-12-01 | Drug product | 2026-06-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N210632-002 | 9782376 | 2036-12-01 | Drug product | 2019-06-11 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N210632-003 | 10398669 | 2036-12-01 | Drug product | 2019-09-13 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N210632-003 | 11135190 | 2036-12-01 | Drug product | 2021-10-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N210632-003 | 12636270 | 2036-12-01 | Drug product | 2026-06-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N210632-003 | 9782376 | 2036-12-01 | Drug product | 2019-06-11 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N210632-001 | 10398669 | 2036-12-01 | Drug product | 2019-09-13 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N210632-001 | 11135190 | 2036-12-01 | Drug product | 2021-10-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N210632-001 | 12636270 | 2036-12-01 | Drug product | 2026-06-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N210632-001 | 9782376 | 2036-12-01 | Drug product | 2019-06-11 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N210632-002 | 10398669 | 2036-12-01 | Drug product | 2019-09-13 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N210632-002 | 11135190 | 2036-12-01 | Drug product | 2021-10-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N210632-002 | 12636270 | 2036-12-01 | Drug product | 2026-06-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N210632-002 | 9782376 | 2036-12-01 | Drug product | 2019-06-11 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N210632-003 | 10398669 | 2036-12-01 | Drug product | 2019-09-13 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N210632-003 | 11135190 | 2036-12-01 | Drug product | 2021-10-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N210632-003 | 12636270 | 2036-12-01 | Drug product | 2026-06-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N210632-003 | 9782376 | 2036-12-01 | Drug product | 2019-06-11 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N210632-001 | 10398669 | 2036-12-01 | Drug product | 2019-09-13 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N210632-001 | 11135190 | 2036-12-01 | Drug product | 2021-10-07 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N210632-001 | 9782376 | 2036-12-01 | Drug product | 2019-06-11 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N210632-002 | 10398669 | 2036-12-01 | Drug product | 2019-09-13 | 011fe1cb6892… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Fresenius Kabi USA, LLC | 08f4b1f8-6807-47e7-bef8-8d1972aa0557 | 2025-03-17 | Boxed warning, Warnings, Adverse reactions | 210632 NDA210632 63323-885 63323-895 63323-890 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Fresenius Kabi USA, LLC | 388a1f15-8c1c-46a5-997f-7f326f696b59 | 2020-12-04 | Boxed warning, Warnings, Adverse reactions | 210632 NDA210632 63323-885 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Fresenius Kabi USA, LLC | 50b1c8a4-75b6-49c8-80fc-3841ee80b183 | 2020-12-04 | Boxed warning, Warnings, Adverse reactions | 210632 NDA210632 63323-885 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 63323-885 | Levothyroxine Sodium | Levothyroxine Sodium | Fresenius Kabi USA, LLC | NDA | Current |
| 63323-885 | Levothyroxine Sodium | Levothyroxine Sodium | Fresenius Kabi USA, LLC | NDA | Current |
| 63323-885 | Levothyroxine Sodium | Levothyroxine Sodium | Fresenius Kabi USA, LLC | NDA | Current |
| 63323-890 | Levothyroxine Sodium | Levothyroxine Sodium | Fresenius Kabi USA, LLC | NDA | Current |
| 63323-895 | Levothyroxine Sodium | Levothyroxine Sodium | Fresenius Kabi USA, LLC | NDA | Current |